Endpoints News 14 avr. 2026 Parker Institute doubles down on cancer vaccines as part of ongoing reboot
Endpoints News 14 avr. 2026 FDA approves Travere's Filspari as first drug for the kidney disease FSGS
Endpoints News 13 avr. 2026 White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says
Endpoints News 13 avr. 2026 Neomorph raises $100M for molecular glues; Spyre's ulcerative colitis data
Endpoints News 13 avr. 2026 Revolution Medicines' pancreatic cancer drug doubles survival time in Phase 3
Endpoints News 13 avr. 2026 Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial
Endpoints News 11 avr. 2026 More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more
Endpoints News 10 avr. 2026 Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s push
Endpoints News 10 avr. 2026 FDA rejects Replimune cancer therapy, saying company didn't resolve trial doubts